Advisory Board
Annette Alaeus, MD PhD
A highly experienced infection specialist with a background as Medical Director at Bristol Myers Squibb. Annette is currently a Senior Consultant and a member of the Medical Quality Team at Kry, which had particular involvement in their “Global Team Covid-19”. She brings expertise from medical R&D and regulatory matters.
Patrik Gille-Johnson, MD
A Medical Doctor and clinician for many years at Danderyds Sjukhus (Sweden) and Karolinska University Hospital (Sweden). As an MD Infectious Diseases Consultant, Patrik has further deepened his understanding of the challenges of antimicrobial resistance and the need for novel therapeutic options. He advises the company from the perspective of the clinical need and use.
Mikael Thomsen, PhD
An expert drug developer with more than 25 years’ experience from the pharmaceutical industry. Mikael has a PhD in pharmacology & toxicology and has worked at Novartis Pharma, Novo Nordisk and various European biotech companies where he held roles such as Chief Development Officer, CSO and Head of R&D. He also co-founded several biotech companies himself and has worked for the U.S. Food and Drug Administration (FDA).
Tomas N Gustafsson, MD PhD
A Senior Consultant at the Infectious Disease Clinic at Sunderby Hospital and a Senior Lecturer at the Department of Clinical Microbiology at Umeå University. Tomas brings combined expertise from the clinic and academic research. Primary research interest includes early antibiotic development and development of methods to help bridge gaps in the antibiotic R&D pipeline. He has scientific experience from working with bacterial thioredoxin systems.